Research letter
Patients with hidradenitis suppurativa may suffer from neuropathic pain: A Finnish multicenter study

https://doi.org/10.1016/j.jaad.2019.11.016Get rights and content

First page preview

First page preview
Click to open first page preview

References (5)

There are more references available in the full text version of this article.

Cited by (13)

  • Hidradenitis suppurativa: Basic considerations for its approach: A narrative review

    2021, Annals of Medicine and Surgery
    Citation Excerpt :

    Regarding chronic pain, the use of NSAIDs is recommended as a first line and as a second line there are pregabalin, gabapentin, selective serotonin reuptake inhibitors and serotonin-norepinephrine reuptake inhibitors [25–31]. The management of the HS will be carried out depending on the Hurley classification (Table 4); Thus, for stage I, topical clindamycin 1% can be used, it has been shown to reduce pustules but has no effect on inflammatory nodules or abscesses [28], so the mainstay is management with systemic antibiotics with tetracyclines, being of choice doxycycline at a dose of 100 mg every 12 h. Topical clindamycin (0.1%) twice daily was found to be as effective as oral tetracyclines (500 mg) for stage I lesions [4]. In the second line for stage I but first line for stage II, rifampicin associated with clindamycin, both at doses of 300 mg twice a day for 10 days, with a response range of 71–85% but with the risk of infection by Clostridium difficile [31–34].

  • Pain management in hidradenitis suppurativa and a proposed treatment algorithm

    2021, Journal of the American Academy of Dermatology
  • What's new in clinical dermatology?

    2020, Annales de Dermatologie et de Venereologie
View all citing articles on Scopus

Funding sources: The design, study conduct, and financial support for the study were provided by AbbVie. AbbVie participated in the interpretation of data, review, and approval of the publication.

Conflicts of interest: Dr Huilaja has received educational grants from CSL Behring, Shire, Janssen-Cilag, Novartis, AbbVie, and LEO Pharma; honoraria from Novartis, Sanofi Genzyme, and UCB Pharma for consulting and/or speaking; and is an investigator for AbbVie. Dr Lipitsä has received educational grants from AbbVie and is an investigator for AbbVie. Dr Harvima has received educational grants from AbbVie. Dr Vihervaara has received educational grants from AbbVie, Jansen, Novartis, and Celgene. Dr Pasternack has received educational grants from AbbVie, Janssen, LEO Pharma, Novartis, Pfizer, and Sanofi Genzyme; honoraria from AbbVie, Galenica, Eli Lilly, Janssen, Novartis, and Sanofi Genzyme for consulting and/or speaking; participated in clinical studies sponsored by AbbVie, Novartis, Eli Lilly, and Regeneron, and is an investigator for AbbVie. Dr Kouri has received educational grants from Pfizer. Authors Ranta and Hirvonen are employees of AbbVie and may or may not own AbbVie stock. Author Sintonen has no conflicts of interest.

IRB approval status: The Tampere University Hospital Ethics Committee approved this study (R16017/2016).

Reprints not available from the authors.

View full text